David A. Siegel Ionis Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,667,611 shares of IONS stock, worth $110 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
2,667,611
Previous 2,092,011
27.51%
Holding current value
$110 Million
Previous $63.1 Million
66.99%
% of portfolio
0.23%
Previous 0.15%
Shares
32 transactions
Others Institutions Holding IONS
# of Institutions
406Shares Held
148MCall Options Held
872KPut Options Held
432K-
Vanguard Group Inc Valley Forge, PA16.7MShares$688 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16MShares$661 Million0.4% of portfolio
-
Capital World Investors Los Angeles, CA12.5MShares$516 Million0.08% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$425 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.85MShares$323 Million5.5% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $5.85B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...